探索去势抵抗性前列腺癌患者的闪烁现象:恩扎卢胺诱导的PSMA上调在PSMA PET中观察到
回顾性临床队列研究纳入9例接受恩扎卢胺治疗的转移性去势抵抗性前列腺癌男性,比较用药前后PSMA PET/CT,56%的评估病灶(n=42)SUVmax显著升高≥20%,1例(11%)出现新病灶,危及器官PSMA表达基本无变化,结论认为恩扎卢胺诱导PSMA上调可能增强诊疗策略,需进一步探索闪烁现象的临床意义。
要点
- 恩扎卢胺治疗后56%的评估病灶(n=42)PSMA表达显著升高,SUVmax增幅≥20%。
- 1例患者(11%)出现新的PSMA阳性病灶。
- 危及器官PSMA表达基本无变化,提示反应具有肿瘤特异性。
核心结论
- 恩扎卢胺在转移性去势抵抗性前列腺癌中诱导PSMA上调,可能增强诊断和治疗策略。
- 需进一步探索闪烁现象的临床意义。
研究设计与样本
- 回顾性临床队列研究,纳入9例接受恩扎卢胺治疗的转移性去势抵抗性前列腺癌男性。
- 在恩扎卢胺开始前后行PSMA PET/CT,肉眼和半定量评估病灶及危及器官。
- 闪烁现象定义为现有病灶SUVmax显著升高≥20%或出现新的PSMA阳性病灶。
主要发现
- 恩扎卢胺暴露后56%的评估病灶(n=42)PSMA表达显著升高。
- 1例患者(11%)检测到新病灶。
- 危及器官PSMA表达基本未受影响,提示肿瘤特异性反应。
关键数值与推荐
- 闪烁现象判定标准:现有病灶SUVmax显著升高≥20%或出现新的PSMA阳性病灶。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需进一步探索闪烁现象的临床意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Androgen receptor-targeting agents, particularly enzalutamide, show promise in enhancing prostate cancer diagnostic and therapeutic strategies by modulating prostate-specific membrane antigen (PSMA). Methods: A retrospective clinical cohort study investigated 9 men with metastatic castration-resistant prostate cancer on enzalutamide. PSMA PET/CT scans were obtained before and after enzalutamide initiation to assess PSMA expression changes. Lesions and organs at risk were evaluated visually and semiquantitatively. The flare phenomenon was characterized by a significant increase (≥20%) in the SUVmax of existing lesions or the appearance of new PSMA-positive lesions. Results: Exposure to enzalutamide led to a significant PSMA expression increase in 56% of assessed lesions (n = 42), with new lesions detected in 1 patient (11%). PSMA expression in organs at risk remained largely unaffected, indicating a tumor-specific response. Conclusion: Enzalutamide induces PSMA upregulation in metastatic castration-resistant prostate cancer, potentially enhancing diagnostic and therapeutic strategies. Further exploration of the flare phenomenon's clinical implications is warranted.
引用
- van der Gaag S, Vis AN, Bartelink IH, et al. Exploring the Flare Phenomenon in Patients with Castration-Resistant Prostate Cancer: Enzalutamide-Induced PSMA Upregulation Observed on PSMA PET. J Nucl Med. 2025. PMID: 39915123. doi:10.2967/jnumed.124.268340
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。